| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910506389503321 |
|
|
Autore |
Saeed Haitham |
|
|
Titolo |
Essentials of aerosol therapy in critically ill patients / / Haitham Saeed [and three others] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2021] |
|
©2021 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (245 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Aerosol therapy |
Critical care medicine |
Internal medicine |
Aerosolteràpia |
Medicina intensiva |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Contents -- Abbreviations -- Chapter 1: The Type of Patients Requiring Aerosol Therapy (to Treat What and Where?) -- 1.1 Introduction -- 1.2 Differences Between Pediatrics and Adults Influencing Aerosol Delivery -- 1.3 Diseases Treated by Aerosol Therapy -- 1.3.1 Asthma -- 1.3.1.1 Asthma Diagnosis -- 1.3.1.2 Asthma Phenotypes -- 1.3.1.3 Asthma Management -- Non-pharmacological Treatment -- Pharmacological Treatment -- 1.3.1.4 Asthma Exacerbations -- Prevention of Exacerbations -- Management of Asthma Exacerbations -- 1.3.2 Chronic Obstructive Pulmonary Disease -- 1.3.2.1 COPD Diagnosis -- 1.3.2.2 Differences Between COPD and Asthma Diagnosis -- 1.3.2.3 Management of Stable COPD -- 1.3.2.4 Management of COPD Exacerbations -- References -- Chapter 2: Types of Mechanical Ventilation -- 2.1 Mechanical Ventilation -- 2.2 Non-invasive Ventilation -- 2.3 Non-invasive Negative Pressure Ventilation -- 2.4 Non-invasive Positive Pressure Ventilation -- 2.5 Ventilation Modes -- 2.6 Configuration of NIV Circuit -- 2.7 Invasive Ventilation -- 2.8 Endotracheal Intubation -- 2.9 Tracheostomy -- |
|
|
|
|
|
|
|
|
|
2.10 Complications of Mechanical Ventilation -- 2.11 Acute Respiratory Distress Syndrome (ARDS) -- 2.12 Ventilator-Associated Pneumonia (VAP) -- 2.13 Pneumothorax -- 2.14 Atelectasis -- 2.15 Pulmonary Edema -- 2.16 Pleural Effusion -- References -- Chapter 3: Oxygen Delivery Systems and Nasally Ventilated Patients -- 3.1 Introduction -- 3.2 Oxygen Device -- 3.3 Clinical Benefits Offered by HFNC -- 3.3.1 Improvement of Mucociliary Clearance -- 3.3.2 Anatomical Dead Space Washout -- 3.3.3 Positive End-Expiratory Pressure (PEEP) Effect -- 3.3.4 Provision of the Stable Fraction of Inspired Oxygen -- 3.4 Attenuation of Inspiratory Resistance (Work of Breathing) -- 3.4.1 By Providing Adequate Flow -- 3.4.2 By Supplying Adequately Heated and Humidified Gas. |
3.4.2.1 Potential Clinical HFNC Applications -- 3.5 Obstructive Airways Diseases -- 3.6 Hypoxemic Respiratory Failure -- 3.7 Hypercapnic Respiratory Failure -- 3.8 Acute Cardiogenic Pulmonary Edema (ACPE) -- 3.9 Respiratory Infection -- 3.10 Post-extubation -- 3.11 Do-Not-Intubate Patients and Palliative Care -- 3.12 Home Oxygen Therapy or Long Term Oxygen Therapy (LTOT) -- 3.13 Oxygen Concentrators -- 3.14 Compressed Gas Cylinders -- 3.15 Liquid Oxygen Systems -- References -- Chapter 4: Special Needs for Neonates, Infants, and Toddler -- 4.1 Introduction -- 4.2 Differences Between Pediatric and Adult Patients in the Delivery of Inhaled Medications -- 4.3 Age Is a Factor for Choosing the Best Aerosol-Generating Device -- 4.4 Patient-Related Factors -- 4.5 Selection of Aerosol-Generating Devices -- 4.6 Aerosol Generating Devices -- 4.7 Nebulizers -- 4.7.1 Jet Nebulizer -- 4.7.2 Ultrasonic Nebulizers -- 4.7.3 Vibrating Mesh Nebulizers -- 4.8 Pressurized Metered-Dose Inhalers -- 4.9 Dry Powder Inhalers -- 4.10 Selection of Aerosol Therapy Interface -- 4.11 Valved Holding Chamber and Spacers -- References -- Chapter 5: Transitioning Aerosol from Hospital to Home -- Role of Training and Follow-Up -- 5.1 Challenges of Aerosol Therapy -- 5.2 Factors Affecting Adherence to Aerosol Therapy -- 5.2.1 The Aerosol Generating Devices -- 5.2.2 Drug-Related Factors -- 5.2.3 Healthcare Professional Related Factors -- 5.3 Factors Related to the Patient -- 5.4 Role of Counseling in Patient Adherence -- 5.4.1 Counseling Sessions -- 5.5 Patient Preference-Based Inhaler Selection -- 5.5.1 Inhaler Labeling -- 5.5.2 Aerosol Therapies Follow Up -- 5.5.3 Evaluation of Patient Inhaler Usage Technique -- 5.5.4 Inhalation Manager -- 5.5.5 Aerosol Inhalations Monitor (AIM) -- 5.5.6 Mag-Flo Inhaler -- 5.5.7 Turbutest -- 5.5.8 2Tone Trainer -- 5.5.9 In-Check DIAL. |
5.5.10 Trainhaler and Flo-Tone -- 5.5.11 Clip-Tone E -- 5.6 Monitoring Patient Adherence to Aerosol Therapy -- 5.7 Clinical Judgment on Therapy -- 5.8 Self-Reports by Patients -- 5.9 Electronic Monitoring Device -- 5.10 Laboratory Measurements of Medications and Response -- 5.11 Pharmacy Registered Data -- 5.12 Assessment Tools for Aerosol Therapy and Disease Control -- 5.12.1 Questionnaires in Asthma -- 5.12.2 Asthma Control Questionnaire -- 5.12.3 Asthma Control Test -- 5.12.4 Asthma Therapy Assessment Questionnaire (ATAQ) -- 5.12.5 Test for Respiratory and Asthma Control in Kids -- 5.12.6 Questionnaires for Assessment of COPD -- References -- Chapter 6: The Aerosol Generators Available for Critically Ill Patient -- 6.1 Introduction -- 6.2 Discussion and Analysis of Main Topics -- 6.2.1 Nebulizers -- 6.2.1.1 Air-Jet Nebulizer (JNs) -- 6.2.1.2 Ultrasonic Nebulizers (USNs) -- 6.2.1.3 Vibrating Mesh Nebulizer (VMNs) -- 6.2.2 Pressurized Metered Dose Inhalers (pMDIs) -- 6.2.2.1 Add-on Devices (Spacers) -- 6.2.3 Dry Powder Inhalers (DPIs) -- 6.2.4 Soft Mist Inhalers (SMIs) -- 6.3 Conclusion -- References -- Chapter 7: Mechanisms of Aerosol Lung Deposition -- 7.1 Principles of Aerosol |
|
|
|
|
|
|
|
Delivery -- 7.2 Physical Principles that Control Aerosol Delivery and Deposition -- 7.2.1 Particle Size -- 7.2.2 Inertial Impaction -- 7.2.3 Gravitational Sedimentation -- 7.2.4 Brownian Motion and Diffusion -- 7.2.5 Electrostatic Attraction -- 7.2.6 Variables Related to the Patient -- 7.2.7 Deposition in the Oropharyngeal Regions -- 7.3 Oral Deposition for the Dry Powder Inhalers (DPIs) -- 7.3.1 Lung Clearance Mechanisms -- 7.3.2 The Optimal Site for Aerosol Therapy Deposition for Management of Lung Diseases -- 7.4 Optimal Site of Aerosol Therapy Deposition for Management of Systemic Diseases -- References. |
Chapter 8: Factors Affecting Aerosol Deposition in Critically Ill Patient -- 8.1 Introduction -- 8.2 Discussion and Analysis of Main Topics -- 8.2.1 Ventilator-Related Factors -- 8.2.2 Circuit-Related Factors -- 8.2.3 Device-Related Factors -- 8.2.4 Drug-Related Factors -- 8.2.5 Patient-Related Factors -- 8.3 Conclusion -- References -- Chapter 9: Inhaled Medications Employed in Critically Ill Patients -- 9.1 Introduction -- 9.2 Discussion and Analysis of Main Topics -- 9.2.1 Inhaled Medications Employed During Mechanical Ventilation (MV) -- 9.2.1.1 Bronchodilators -- 9.2.1.2 Prostanoids -- 9.2.1.3 Surfactant -- 9.2.1.4 Antibiotics/Antibacterial -- 9.2.1.5 Antiviral -- 9.2.1.6 Mucolytic Agents -- 9.2.1.7 Corticosteroids -- 9.2.1.8 Miscellaneous -- 9.2.2 Common Applications of Aerosol Therapy in Critical Care -- 9.2.3 Effect of Dosing -- 9.2.4 Effect of Administration Technique -- 9.2.5 Limitations of Aerosol Therapy in Critical Care -- 9.3 Conclusion -- References -- Chapter 10: Aerosol Therapies During High Flow Oxygen Therapy -- 10.1 Introduction -- 10.2 Factors Affecting Aerosol Delivery Within High Flow Oxygen System -- 10.2.1 Flow Rate of Gas -- 10.2.2 The Type of Aerosol Generator and Its Position Within the HFNC Circuit -- 10.2.3 Density of Gas -- 10.2.4 Interface -- References -- Chapter 11: Methods of Detecting Aerosol Delivery to the Lung -- 11.1 Introduction -- 11.2 Particle Size Distribution -- 11.3 Measuring Aerosol Particle Distribution with Inertial Impaction -- 11.4 Twin Stage Impinger -- 11.5 Marple-Miller Cascade Impactor -- 11.6 Multistage Liquid Impinger -- 11.7 Anderson Cascade Impactor -- 11.8 Next-Generation Impactors -- 11.9 Light Diffraction Methods -- 11.10 Laser Diffraction -- 11.11 Pulmonary Function Tests -- 11.12 Spirometry -- 11.13 Models Used for Aerosol Delivery Quantification -- 11.14 In-Vitro Models. |
11.15 In-Vitro Determination of Emitted Dose -- 11.16 In-Vitro Model for Characterization of Aerosol Particle Size Via Inertial Impaction -- 11.16.1 In-Vivo Models -- 11.16.2 Pharmacokinetics Model -- 11.16.3 Ex-Vivo Models -- 11.16.4 Imaging Models -- 11.16.5 Data Modeling -- References -- Chapter 12: Monitoring Plans and Weaning Protocols for Critically Ill Patients -- 12.1 Introduction -- 12.2 Discussion and Analysis of Main Topics -- 12.2.1 Monitoring Patient During Invasive Mechanical Ventilation (IMV) -- 12.2.1.1 Monitoring of Ventilator Parameters During IMV -- 12.2.1.2 Monitoring Spontaneous Breathing During IMV -- Monitoring through Esophageal Pressure (Pes) -- Transpulmonary Pressure (PL) -- Inspiratory Muscle Pressure (Pmus) -- Transdiaphragmatic Pressure (Pdi) -- Monitoring Through Occlusion Maneuvers -- Inspiratory Occlusion Maneuver -- Expiratory Occlusion Maneuver -- Airway Occlusion Pressure (P0.1) -- Monitoring Through Electrical Activity of the Diaphragm (EAdi) -- Monitoring Through Diaphragm Ultrasound -- 12.2.1.3 Monitoring of ETT -- 12.2.1.4 Monitoring of TST -- 12.2.2 Weaning from IMV -- 12.2.3 Monitoring of Patient During NIV -- 12.2.3.1 Monitoring of Clinical Parameters During NIV -- 12.2.3.2 Monitoring of Special Laboratory Indices during NIV -- 12.2.3.3 Monitoring of Lung Functions |
|
|
|
|
|
|
|
|
|
|
|
and Ventilator Parameters During NIV -- 12.2.4 Optimizing Ventilator Settings During NIV -- 12.2.5 Weaning from NIV -- 12.3 Conclusion -- References. |
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910716492303321 |
|
|
Titolo |
Collecting the revenue from customs, 1927. Communication from the President of the United States transmitting proposed legislation affecting the use of an existing appropriation for the Treasury Department for the fiscal year ending June 30, 1927. March 2 (calendar day, March 3), 1927. -- Read, referred to the Committee on Appropriations, and ordered to be printed |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
[Washington, D.C.] : , : [U.S. Government Printing Office], , 1927 |
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (2 pages) |
|
|
|
|
|
|
Collana |
|
Senate document / 69th Congress, 2nd session. Senate ; ; no. 243 |
[United States congressional serial set] ; ; [serial no. 8713] |
|
|
|
|
|
|
|
|
Altri autori (Persone) |
|
CoolidgeCalvin <1872-1933.> |
|
|
|
|
|
|
Soggetti |
|
Fees, Administrative |
Customs administration |
Executive departments - Reorganization |
Administrative agencies - Reorganization |
Civil service |
Legislative materials. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Batch processed record: Metadata reviewed, not verified. Some fields updated by batch processes. |
FDLP item number not assigned. |
|
|
|
|
|
|
|
| |